BiotechTube
Vasoptic Medical

Vasoptic Medical

Rochester, United States· Est.
vasoptic.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Vasoptic Medical is a privately-held developer of advanced blood flow imaging systems based on Laser Speckle Contrast Imaging (LSCI). Founded in 2014 and headquartered in Rochester, New York, the company targets the cardiovascular, diagnostics, and medical device sectors with its non-invasive, dye-free technology. Its primary products, the XyCAM and VasoVUE imagers, are positioned as complementary tools to existing angiography methods, offering dynamic flow data for research and clinical use in conditions like glaucoma, diabetic retinopathy, and systemic vascular diseases. The company is currently in an early commercial stage, engaging with the research community and beginning clinical adoption.

GlaucomaDiabetic RetinopathyRetinopathy of PrematurityCardiovascular Diseases

Technology Platform

Laser Speckle Contrast Imaging (LSCI) for non-invasive, real-time, video-rate visualization and quantification of pulsatile blood flow dynamics without contrast agents.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The growing focus on vascular health in chronic diseases like glaucoma and diabetes creates a demand for functional imaging beyond static anatomy.
The technology's non-invasive, dye-free nature and ability to provide dynamic flow metrics offer a potential competitive edge in both clinical diagnostics and research tool markets, with applications extendable beyond ophthalmology to other microvascular monitoring fields.

Risk Factors

Major risks include proving definitive clinical utility over established standards to drive adoption, competing with large, integrated players in ophthalmic imaging, and overcoming the significant regulatory and reimbursement hurdles required for widespread clinical use.
Financial sustainability depends on successful capital raises to bridge from research sales to clinical commercialization.

Competitive Landscape

Vasoptic competes indirectly with dominant ophthalmic imaging companies (Zeiss, Heidelberg, Optovue) whose OCT-A platforms are the standard for non-invasive perfusion mapping. It differentiates by providing dynamic flow data rather than static vessel maps. It also positions against invasive dye-based angiography (fluorescein, ICG) by being non-invasive. Its primary competition is for budget and proving additive value in a crowded diagnostic workflow.

More companies in Diagnostics & Precision Medicine →More companies in United States →